APA (7th ed.) Citation

Schuster, S. J., Tam, C. S., Borchmann, P., Worel, N., McGuirk, J. P., Holte, H., . . . Maziarz, R. T. (2021). Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): A multicentre, open-label, single-arm, phase 2 study. The lancet oncology, 22(10), 1403-1415. https://doi.org/10.1016/S1470-2045(21)00375-2

Chicago Style (17th ed.) Citation

Schuster, Stephen J., et al. "Long-term Clinical Outcomes of Tisagenlecleucel in Patients with Relapsed or Refractory Aggressive B-cell Lymphomas (JULIET): A Multicentre, Open-label, Single-arm, Phase 2 Study." The Lancet Oncology 22, no. 10 (2021): 1403-1415. https://doi.org/10.1016/S1470-2045(21)00375-2.

MLA (9th ed.) Citation

Schuster, Stephen J., et al. "Long-term Clinical Outcomes of Tisagenlecleucel in Patients with Relapsed or Refractory Aggressive B-cell Lymphomas (JULIET): A Multicentre, Open-label, Single-arm, Phase 2 Study." The Lancet Oncology, vol. 22, no. 10, 2021, pp. 1403-1415, https://doi.org/10.1016/S1470-2045(21)00375-2.